Paper7066166
Spironolactone dose-response relationships in healthy subjects.
McInnes GT and 3 others. Br J Clin Pharmacol, 1982. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Spironolactone dose-response relationships in healthy subjects. Papers, record 7066166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7066166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Electrolytes | Major topic |
| Spironolactone | Major topic |
| Adult | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Interactions | |
| Fludrocortisone | |
| Humans | |
| Male | |
| Natriuresis | |
| Potassium |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5025912 | High doses of spironolactone in the treatment of liver cirrhosis with ascites. | Br J Clin Pract | 1972 | https://conductscience.org/library/papers/5025912 | PubMed |
| 2 | 4853286 | Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure. | Eur J Clin Pharmacol | 1974 | https://conductscience.org/library/papers/4853286 | PubMed |
| 3 | 1100306 | Relative potency of prorenoate and spironolactone in normal man. | Clin Pharmacol Ther | 1975 | https://conductscience.org/library/papers/1100306 | PubMed |
| 4 | 1261153 | Spironolactone. I. Disposition and metabolism. | Clin Pharmacol Ther | 1976 | https://conductscience.org/library/papers/1261153 | PubMed |
| 5 | 1261155 | Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels. | Clin Pharmacol Ther | 1976 | https://conductscience.org/library/papers/1261155 | PubMed |
| 6 | 780038 | Spironolactone and potassium canrenoate in normal man. | Clin Pharmacol Ther | 1976 | https://conductscience.org/library/papers/780038 | PubMed |
| 7 | 183514 | Agonist and antimineralocorticoid activities of spirolactones. | Am J Physiol | 1976 | https://conductscience.org/library/papers/183514 | PubMed |
| 8 | 318952 | Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension. | Clin Pharmacol Ther | 1977 | https://conductscience.org/library/papers/318952 | PubMed |
| 9 | 858213 | Spironolactone and canrenoate-K: relative potency at steady state. | Clin Pharmacol Ther | 1977 | https://conductscience.org/library/papers/858213 | PubMed |
| 10 | 356569 | Spironolactone. | Am Heart J | 1978 | https://conductscience.org/library/papers/356569 | PubMed |
| 11 | 7357793 | Activity of sulfur-containing intermediate metabolites of spironolactone. | Clin Pharmacol Ther | 1980 | https://conductscience.org/library/papers/7357793 | PubMed |
| 12 | 7214797 | Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7214797 | PubMed |
| 13 | 7249505 | Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7249505 | PubMed |
| 14 | 7332740 | Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency. | Br J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7332740 | PubMed |
| 16 | 13703392 | Aldosterone antagonists. | N Y State J Med | 1961 | https://conductscience.org/library/papers/13703392 | PubMed |
| 17 | 13743603 | The effect of an aldosterone antagonist on the renal response to sodium restriction. | Clin Sci | 1961 | https://conductscience.org/library/papers/13743603 | PubMed |
| 18 | 14408392 | Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. | Endocrinology | 1960 | https://conductscience.org/library/papers/14408392 | PubMed |
| 19 | 13887873 | The aldosterone blocking effects of spirolactones. | Jpn J Pharmacol | 1962 | https://conductscience.org/library/papers/13887873 | PubMed |
| 20 | 13899372 | A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. | J Pharmacol Exp Ther | 1962 | https://conductscience.org/library/papers/13899372 | PubMed |
| 21 | 13975085 | Human assay of electrolyte-active steroids and their antagonists. | Clin Sci | 1962 | https://conductscience.org/library/papers/13975085 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42752325 | Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia. | Ann Med | 2026 | https://conductscience.org/library/papers/42752325 | PubMed |
| 39402039 | Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study. | Nat Commun | 2024 | https://conductscience.org/library/papers/39402039 | PubMed |
| 39204148 | Real-World Application of a Quantitative Systems Pharmacology (QSP) Model to Predict Potassium Concentrations from Electronic Health Records: A Pilot Case towards Prescribing Monitoring of Spironolactone. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39204148 | PubMed |
| 35776281 | A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone. | J Pharmacokinet Pharmacodyn | 2022 | https://conductscience.org/library/papers/35776281 | PubMed |
| 29785539 | The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale. | Cardiol Ther | 2018 | https://conductscience.org/library/papers/29785539 | PubMed |
| 28507171 | First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis. | Hypertension | 2017 | https://conductscience.org/library/papers/28507171 | PubMed |
| 24133446 | PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. | Front Pharmacol | 2013 | https://conductscience.org/library/papers/24133446 | PubMed |
| 23070570 | Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. | Nat Rev Nephrol | 2012 | https://conductscience.org/library/papers/23070570 | PubMed |
| 6386025 | Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects. | Br J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6386025 | PubMed |
| 3884320 | Diuretics. Clinical pharmacology and therapeutic use (Part II). | Drugs | 1985 | https://conductscience.org/library/papers/3884320 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7066166
GET https://conductscience.org/api/papers/v1/7066166/authors